MicroGenDX provides diagnostic testing services.

MicroGenDX

IPhone / Mobile Compatible

Viewport Meta

SSL by Default

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Font API

Google Analytics

DNSSEC

Chief Technology Officer

Eric Rees

Business Management

Rick Martin

Head of Marketing

Grant Weiss

Sales and Support

Lars Keeley

Marketing and Product

James Compagno

Strategic Corporate Accounts Manager, National Sales Director - Advanced Bio Data Labs at MicroGenDX

Joe Hagedorn

Ken Perry

Kerstin Martin

National Sales Director Wound Division

Kristie Fuller

Director of Software Development

Lars Koenig

Randall Wolcott

Founder

Medical Companies With More Than 10 Employees (Top 10K)

Texas Companies With Less Than $1B in Revenue (Top 10K)

Texas Companies With More Than 100 Employees (Top 10K)

Health Diagnostics Companies With Fewer Than 1000 Employees (Top 10K)

MicroGenDX provides next-generation DNA sequencing (NGS) for clinical diagnostics. MicroGenDX has become the industry leader in rapid turnaround and affordability for comprehensive Next-generation sequencing (NGS) and qPCR testing for clinical diagnostics. MicroGenDX is CLIA-licensed and CAP-accredited and has been the trusted research partner for the CDC, U.S. Army, NASA, and the FDA. MicroGenDX has published over 70 clinical trials and is the most experienced molecular diagnostic laboratory with some 1.5 million samples processed. Over 80,000medical professionals rely on MicroGenDX clinical diagnostics MicroGenDX also offers over 30 specialized clinical diagnostic tests for a comprehensive array of medical specialties and infection types.

Lubbock

Texas

United States

North America

Council Post: Changing Medical Practice: Opportunities And Challenges

Four Groundbreaking Studies From NGS Pioneers MicroGenDX to Be Presented for the First Time to Attendees of the ...

Four Groundbreaking Studies From NGS Pioneers MicroGenDX...

MicroGenDX Launches Its Patient-Focused Website to Streamline Access to Microbial Testing

Preventing postoperative infections one NGS assay at a time

MicroGenDX Resolves Dispute with AdventHealth over COVID-19 Testing Services

Combines qPCR and NGS to detect all bacteria and fungi in a sample, providing results in 3.5 days and identifying antimicrobial resistance genes within 24-48 hours.

Utilizes qPCR+NGS to diagnose challenging infections, especially in patients not responding to current treatments or with culture-negative infections.

Employs qPCR+NGS to identify bacterial contamination and manage infections in capsular contracture and breast implants.

Recommends DNA diagnostics for chronic wound management, providing precise species identification and estimated quantification of organisms in the specimen.

Offers DNA diagnostics for pulmonary infections, identifying mycobacteria, anaerobes, and fungi that culture does not, with results in 3.5 days.

Uses qPCR+NGS for diagnosing urinary tract infections, prostatitis, and other urological conditions, identifying a wide range of microbial species in urine samples.

The Netherlands

Europe

United Kingdom

India

Asia

Peru

South America

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 16, 2024 6:13 AM	6828e47d
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 16, 2024 6:13 AM	bfe67638
crunchbase trigger	general	Nov 27, 2024 12:50 PM	fd217acd
crunchbase profile	general	Nov 28, 2024 9:12 AM	81bca4b1
li profile	general
translate crunchbase fundingrounds	general	Nov 28, 2024 10:19 AM	20dc574d
peers	general	Oct 16, 2024 6:13 AM	8bc03a64
news basic	general	Oct 16, 2024 6:13 AM	36325d73
bundesanzeiger	filings
financials download nd	financials
private financials	financials

MICR

COM:MICROGENDX

MicroGenDX